PL2178915T3 - Przeciwciała anty cd37 - Google Patents

Przeciwciała anty cd37

Info

Publication number: PL2178915T3
Authority: PL; Poland
Prior art keywords: antibodies
Prior art date: 2007-08-09

Application number

PL08787055T

Other languages

English (en)

Inventor

Karl-Heinz Heider

Eric Borges

Elinborg Ostermann

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-09

Filing date

2008-08-08

Publication date

2016-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2178915(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-08-08 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2016-03-31 Publication of PL2178915T3 publication Critical patent/PL2178915T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Environmental Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Oncology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Animal Husbandry (AREA)
Biodiversity & Conservation Biology (AREA)
Mycology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL08787055T 2007-08-09 2008-08-08 Przeciwciała anty cd37 PL2178915T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP07114128		2007-08-09
EP08787055.6A EP2178915B1 (en)	2007-08-09	2008-08-08	Anti cd37 antibodies
PCT/EP2008/060464 WO2009019312A2 (en)	2007-08-09	2008-08-08	Anti cd37 antibodies

Publications (1)

Publication Number	Publication Date
PL2178915T3 true PL2178915T3 (pl)	2016-03-31

Family

ID=38925567

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL08787055T PL2178915T3 (pl)	2007-08-09	2008-08-08	Przeciwciała anty cd37

Country Status (37)

Country	Link
US (7)	US20100189722A1 (pl)
EP (3)	EP2178915B1 (pl)
JP (3)	JP5325216B2 (pl)
KR (1)	KR101593403B1 (pl)
CN (4)	CN105273086A (pl)
AR (2)	AR071242A1 (pl)
AU (1)	AU2008285590B2 (pl)
BR (2)	BRPI0823331A2 (pl)
CA (1)	CA2693464C (pl)
CL (3)	CL2008002349A1 (pl)
CO (1)	CO6251371A2 (pl)
CY (1)	CY1117101T1 (pl)
DK (1)	DK2178915T3 (pl)
EA (2)	EA201200994A1 (pl)
EC (2)	ECSP109946A (pl)
ES (1)	ES2555202T3 (pl)
HK (1)	HK1220708A1 (pl)
HR (1)	HRP20160009T1 (pl)
HU (1)	HUE026221T2 (pl)
IL (1)	IL202645A (pl)
MA (1)	MA32665B1 (pl)
ME (1)	ME02300B (pl)
MY (1)	MY157555A (pl)
NZ (2)	NZ583713A (pl)
PE (3)	PE20140196A1 (pl)
PH (1)	PH12014501812A1 (pl)
PL (1)	PL2178915T3 (pl)
PT (1)	PT2178915E (pl)
RS (1)	RS54359B1 (pl)
SG (1)	SG190657A1 (pl)
SI (1)	SI2178915T1 (pl)
TN (1)	TN2010000068A1 (pl)
TW (2)	TWI535733B (pl)
UA (2)	UA105445C2 (pl)
UY (1)	UY31275A1 (pl)
WO (1)	WO2009019312A2 (pl)
ZA (1)	ZA200908758B (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
PT1912675E (pt)	2005-07-25	2014-05-09	Emergent Product Dev Seattle	Moléculas de ligaçao especificas para cd37 e especificas para cd20
MX380352B (es)	2006-06-12	2025-03-12	Aptevo Res & Development Llc	Proteinas de union multivalentes monocatenarias con funcion efectora.
PE20140196A1 (es) *	2007-08-09	2014-03-19	Boehringer Ingelheim Int	Anticuerpos anti-cd37
JP2010540460A (ja) *	2007-09-24	2010-12-24	トラガラファーマシューティカルズ，インク．	ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
RS51975B (sr)	2008-04-11	2012-02-29	Emergent Product Development Seattle Llc.	Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom
BR112012015740B1 (pt) *	2009-12-23	2020-09-29	Synimmune Gmbh	Anticorpo anti-flt3, seu uso,bem como composição compreendendo o referido anticorpo e molécula de ácido nucleico
NO331080B1 (no) *	2010-01-29	2011-09-26	Nordic Nanovector As	Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
MY177062A (en) *	2010-03-12	2020-09-03	Debiopharm Int Sa	Cd37-binding molecules and immunoconjugates thereof
US20120189618A1 (en) *	2010-07-16	2012-07-26	Boehringer Ingelheim International Gmbh	Superior efficacy of cd37 antibodies in cll blood samples
UA112062C2 (uk)	2010-10-04	2016-07-25	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Cd33-зв'язувальний агент
US20120107317A1 (en) *	2010-10-27	2012-05-03	The University Of Hong Kong	Use of cytoplasmic c-myc for regulating immune responses
EA201391342A1 (ru) *	2011-04-01	2014-11-28	Иммьюноджен, Инк.	Cd37-связывающие молекулы и их иммуноконъюгаты
CN107903325B (zh)	2011-05-16	2021-10-29	埃泰美德(香港)有限公司	多特异性fab融合蛋白及其使用方法
RU2658438C2 (ru) *	2011-12-13	2018-06-21	Нордик Нановектор Аса	Химерное терапевтическое антитело нн1 против cd-37
CN104364651A (zh) *	2012-03-30	2015-02-18	伊缪诺金公司	用于增加基于cd37的疗法的功效的方法
EP2841099A1 (en) *	2012-04-26	2015-03-04	Boehringer Ingelheim International GmbH	Combination of cd37 antibodies with bendamustine
JP2015517512A (ja) *	2012-05-16	2015-06-22	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｄ３７抗体の更なる薬剤との併用
JP2015517511A (ja) *	2012-05-16	2015-06-22	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用
WO2013177367A2 (en) *	2012-05-23	2013-11-28	The Johns Hopkins University	Compounds and methods of use thereof for treating neurodegenerative disorders
WO2014151438A1 (en) *	2013-03-15	2014-09-25	Emergent Product Development Seattle, Llc	Multispecific anti-cd37 antibodies and related compositions and methods
US20160106837A1 (en) *	2013-06-14	2016-04-21	Boehringer Ingelheim International Gmbh	Combination of cd37 antibodies with chlorambucil
WO2015017552A1 (en)	2013-08-01	2015-02-05	Agensys, Inc.	Antibody drug conjugates (adc) that bind to cd37 proteins
US9291244B2 (en)	2014-01-17	2016-03-22	Ford Global Technologies, Llc	Nine speed automatic transmission
EP2966085A1 (en)	2014-07-11	2016-01-13	Boehringer Ingelheim International GmbH	Antibody IgG1 with a modified heavy chain constant region
US10144779B2 (en)	2015-05-29	2018-12-04	Agenus Inc.	Anti-CTLA-4 antibodies and methods of use thereof
EA201792300A1 (ru)	2015-06-08	2018-09-28	Дебиофарм Интернэшнл, С.А.	Комбинации иммуноконъюгата к cd37 и антитела к cd20
TR201816369T4 (tr)	2015-07-28	2018-11-21	Forschungszentrum Borstel Leibniz Lungenzentrum	Endotoksin tayinine yönelik iyileştirilmiş bakteriyel endotoksin testi.
KR102766022B1 (ko)	2015-08-28	2025-02-10	데비오팜 인터네셔날 에스 에이	Cd37 의 검출을 위한 항체 및 검정
BR112018005573A2 (pt)	2015-09-21	2019-01-22	Aptevo Research And Development Llc	?polipeptídeos de ligação a cd3?
CN109476756B (zh)	2016-03-15	2022-05-31	埃泰美德(香港)有限公司	一种多特异性Fab融合蛋白及其用途
EP3535297B1 (en)	2016-11-02	2022-08-10	Debiopharm International, S.A.	Methods for improving anti-cd37 immunoconjugate therapy
MA50949B1 (fr) *	2016-12-07	2023-12-29	Memorial Sloan Kettering Cancer Center	Anticorps anti-ctla-4 et leurs procédés d'utilisation
WO2018132506A1 (en)	2017-01-10	2018-07-19	The General Hospital Corporation	Chimeric antigen receptors based on alternative signal 1 domains
EP3595721B1 (en)	2017-03-16	2025-07-09	The General Hospital Corporation	Chimeric antigen receptors targeting cd37
UA127586C2 (uk)	2017-03-31	2023-10-25	Ґенмаб Холдінґ Б.В.	Біспецифічні анти-cd37-антитіла, моноклональні анти-cd37-антитіла та способи їх застосування
CN118109477A (zh) *	2017-06-27	2024-05-31	瑞泽恩制药公司	包含人源化asgr1基因座的非人动物
JP2021525735A (ja)	2018-05-30	2021-09-27	デビオファームインターナショナル，エス．アー．	抗ｃｄ３７免疫コンジュゲート投薬レジメン
US12275797B2 (en)	2018-06-22	2025-04-15	Genmab Holding B.V.	Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
CN112292140B (zh) *	2018-06-22	2025-03-11	综合医院公司	靶向cd37和cd19的嵌合抗原受体
WO2020004337A1 (ja) *	2018-06-27	2020-01-02	国立大学法人名古屋大学	Ｃｄ３７特異的キメラ抗原レセプター
US12460000B2 (en)	2018-09-07	2025-11-04	Itabmed (Hk) Limited	Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
BR112021006055A2 (pt)	2018-10-04	2021-07-20	Genmab Holding B.V.	composição farmacêutica, uso da composição farmacêutica, e, métodos para induzir a morte celular ou para inibir o crescimento e/ou proliferação de uma célula tumoral e para tratar um indivíduo.
CN114650867A (zh) *	2019-08-30	2022-06-21	齐鲁普吉湾生物治疗公司	抗cd20抗体、抗cd37抗体及它们的混合物
EP4405398A4 (en) *	2021-09-21	2025-10-29	Qilu Puget Sound Biotherapeutics Corp	FC HETERODIMERS ALLOWING THE MANUFACTURE OF FUSION PROTEINS AND BI-SPECIFIC ANTIBODIES
WO2023057595A1 (en)	2021-10-06	2023-04-13	Nordic Nanovector Asa	Humanized hh1 rew
US20250333531A1 (en)	2021-10-06	2025-10-30	Nordic Nanovector Asa	Humanized hh1
JPWO2023068226A1 (pl) *	2021-10-18	2023-04-27
WO2024118480A1 (en) *	2022-11-28	2024-06-06	Epiphany Biosciences	Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses
WO2025083205A1 (en)	2023-10-18	2025-04-24	Debiopharm International S.A.	Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4342566A (en)	1980-02-22	1982-08-03	Scripps Clinic & Research Foundation	Solid phase anti-C3 assay for detection of immune complexes
EP0247091B1 (en)	1985-11-01	1993-09-29	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) *	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
GB8800077D0 (en) *	1988-01-05	1988-02-10	Ciba Geigy Ag	Novel chimeric antibodies
EP0417193B1 (en)	1988-05-27	1993-08-04	Centocor, Inc.	Freeze-dried formulation for antibody products
CA1341351C (en) *	1988-09-06	2002-03-26	Marc D. Better	Production of chimeric mouse-human antibodies with specificity to human tumor antigens
ES2238070T3 (es)	1989-04-21	2005-08-16	Amgen Inc.	Receptor del tnf, proteina ligante del tnf y adn codante para estos.
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
EP1260521B1 (en)	1991-08-14	2007-11-21	Genentech Inc.	Immunoglobulin variants for specific Fc epsilon receptors
DE69231123T2 (de)	1992-03-25	2001-02-15	Immunogen Inc	Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
WO1994029347A1 (en)	1993-06-03	1994-12-22	Therapeutic Antibodies Inc.	Antibody fragments in therapy
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
AU728657B2 (en)	1996-03-18	2001-01-18	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
US5834597A (en)	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU3968897A (en)	1996-08-02	1998-02-25	Bristol-Myers Squibb Company	A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US6991790B1 (en)	1997-06-13	2006-01-31	Genentech, Inc.	Antibody formulation
JP2002505086A (ja)	1998-02-25	2002-02-19	レキシジェンファーマシューティカルズコーポレイション	抗体ベースの融合タンパク質の循環半減期の増強
DE19911329A1 (de)	1998-03-27	2000-09-21	Benes Ivan Friedrich	Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
DK1068241T3 (da)	1998-04-02	2008-02-04	Genentech Inc	Antistofvarianter og fragmenter deraf
GB9809951D0 (en)	1998-05-08	1998-07-08	Univ Cambridge Tech	Binding molecules
JP2003514903A (ja)	1999-11-24	2003-04-22	イムノージェンインコーポレーテッド	タキサンを含有する細胞傷害薬とその治療への利用
DK1242438T3 (da)	1999-12-29	2007-02-12	Immunogen Inc	Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse
ES2649037T3 (es)	2000-12-12	2018-01-09	Medimmune, Llc	Moléculas con semividas prolongadas, composiciones y usos de las mismas
US20030133939A1 (en) *	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
WO2004016753A2 (en)	2002-08-15	2004-02-26	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to trail receptors
US6441163B1 (en)	2001-05-31	2002-08-27	Immunogen, Inc.	Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en)	2001-12-21	2004-04-06	Immunogen Inc.	Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
KR101033196B1 (ko) *	2002-02-14	2011-05-09	이뮤노메딕스, 인코오포레이티드	항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
US20040002587A1 (en)	2002-02-20	2004-01-01	Watkins Jeffry D.	Fc region variants
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
WO2003074679A2 (en)	2002-03-01	2003-09-12	Xencor	Antibody optimization
US6756397B2 (en)	2002-04-05	2004-06-29	Immunogen, Inc.	Prodrugs of CC-1065 analogs
US6596757B1 (en)	2002-05-14	2003-07-22	Immunogen Inc.	Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
JP4459810B2 (ja)	2002-08-14	2010-04-28	マクロジェニクス，インコーポレーテッド	ＦｃγＲＩＩＢ特異的抗体とその利用法
EP3321282A1 (en)	2002-09-27	2018-05-16	Xencor, Inc.	Optimized fc variants and methods for their generation
JP4768439B2 (ja)	2002-10-15	2011-09-07	アボットバイオセラピューティクスコーポレイション	変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
US7960512B2 (en)	2003-01-09	2011-06-14	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006524039A (ja)	2003-01-09	2006-10-26	マクロジェニクス，インコーポレーテッド	変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
MX342007B (es)	2003-05-14	2016-09-09	Immunogen Inc	Composicion de farmaco conjugado.
US7754209B2 (en)	2003-07-26	2010-07-13	Trubion Pharmaceuticals	Binding constructs and methods for use thereof
EP1697520A2 (en)	2003-12-22	2006-09-06	Xencor, Inc.	Fc polypeptides with novel fc ligand binding sites
EP2053062A1 (en)	2004-03-24	2009-04-29	Xencor, Inc.	Immunoglobin variants outside the Fc region
DK2471813T3 (en)	2004-07-15	2015-03-02	Xencor Inc	Optimized Fc variants
WO2006031994A2 (en)	2004-09-14	2006-03-23	Xencor, Inc.	Monomeric immunoglobulin fc domains
WO2006047350A2 (en)	2004-10-21	2006-05-04	Xencor, Inc.	IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
CN102746404B (zh)	2004-11-12	2016-01-20	赞科股份有限公司	对FcRn的结合被改变的Fc变体
PT1912675E (pt) *	2005-07-25	2014-05-09	Emergent Product Dev Seattle	Moléculas de ligaçao especificas para cd37 e especificas para cd20
US20080279850A1 (en)	2005-07-25	2008-11-13	Trubion Pharmaceuticals, Inc.	B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
EP1931709B1 (en) *	2005-10-03	2016-12-07	Xencor, Inc.	Fc variants with optimized fc receptor binding properties
HUE035250T2 (hu)	2005-10-12	2018-05-02	Morphosys Ag	Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása
EP1806365A1 (en)	2006-01-05	2007-07-11	Boehringer Ingelheim International GmbH	Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
CN101990439A (zh)	2007-07-06	2011-03-23	特鲁比昂药品公司	具有置于c末端的特异性结合结构域的结合肽
PE20140196A1 (es) *	2007-08-09	2014-03-19	Boehringer Ingelheim Int	Anticuerpos anti-cd37
RS51975B (sr)	2008-04-11	2012-02-29	Emergent Product Development Seattle Llc.	Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom
AU2009274129B2 (en)	2008-07-21	2016-02-25	Immunomedics Inc.	Structural variants of antibodies for improved therapeutic characteristics
EP2358390A1 (en)	2008-11-13	2011-08-24	Emergent Product Development Seattle, LLC	Cd37 immunotherapeutic combination therapies and uses thereof
US20120189618A1 (en)	2010-07-16	2012-07-26	Boehringer Ingelheim International Gmbh	Superior efficacy of cd37 antibodies in cll blood samples
EP2841099A1 (en) *	2012-04-26	2015-03-04	Boehringer Ingelheim International GmbH	Combination of cd37 antibodies with bendamustine
JP2015517512A (ja) *	2012-05-16	2015-06-22	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｄ３７抗体の更なる薬剤との併用
JP2015517511A (ja) *	2012-05-16	2015-06-22	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用
US20160106837A1 (en)	2013-06-14	2016-04-21	Boehringer Ingelheim International Gmbh	Combination of cd37 antibodies with chlorambucil

2008
- 2008-08-07 PE PE2013000843A patent/PE20140196A1/es not_active Application Discontinuation
- 2008-08-07 PE PE2008001321A patent/PE20090499A1/es active IP Right Grant
- 2008-08-07 PE PE2011000972A patent/PE20120259A1/es active IP Right Grant
- 2008-08-08 ES ES08787055.6T patent/ES2555202T3/es active Active
- 2008-08-08 KR KR1020107002636A patent/KR101593403B1/ko not_active Expired - Fee Related
- 2008-08-08 BR BRPI0823331-4A2A patent/BRPI0823331A2/pt not_active Application Discontinuation
- 2008-08-08 UA UAA201303569A patent/UA105445C2/uk unknown
- 2008-08-08 EP EP08787055.6A patent/EP2178915B1/en active Active
- 2008-08-08 NZ NZ583713A patent/NZ583713A/en not_active IP Right Cessation
- 2008-08-08 RS RS20150817A patent/RS54359B1/sr unknown
- 2008-08-08 EP EP10168244A patent/EP2241577A1/en not_active Withdrawn
- 2008-08-08 US US12/672,378 patent/US20100189722A1/en not_active Abandoned
- 2008-08-08 BR BRPI0815369-8A patent/BRPI0815369A2/pt active Search and Examination
- 2008-08-08 PT PT87870556T patent/PT2178915E/pt unknown
- 2008-08-08 CA CA2693464A patent/CA2693464C/en not_active Expired - Fee Related
- 2008-08-08 EA EA201200994A patent/EA201200994A1/ru unknown
- 2008-08-08 SI SI200831544T patent/SI2178915T1/sl unknown
- 2008-08-08 DK DK08787055.6T patent/DK2178915T3/en active
- 2008-08-08 AU AU2008285590A patent/AU2008285590B2/en not_active Ceased
- 2008-08-08 PL PL08787055T patent/PL2178915T3/pl unknown
- 2008-08-08 EP EP12185691.8A patent/EP2562187B1/en active Active
- 2008-08-08 CN CN201510756148.2A patent/CN105273086A/zh active Pending
- 2008-08-08 WO PCT/EP2008/060464 patent/WO2009019312A2/en not_active Ceased
- 2008-08-08 CN CN2013102616193A patent/CN103396490A/zh active Pending
- 2008-08-08 MY MYPI2010000565A patent/MY157555A/en unknown
- 2008-08-08 UA UAA201002500A patent/UA103005C2/ru unknown
- 2008-08-08 AR ARP080103490A patent/AR071242A1/es not_active Application Discontinuation
- 2008-08-08 TW TW097130378A patent/TWI535733B/zh not_active IP Right Cessation
- 2008-08-08 HU HUE08787055A patent/HUE026221T2/en unknown
- 2008-08-08 EA EA201000274A patent/EA027499B1/ru not_active IP Right Cessation
- 2008-08-08 HR HRP20160009TT patent/HRP20160009T1/hr unknown
- 2008-08-08 ME MEP-2015-191A patent/ME02300B/me unknown
- 2008-08-08 NZ NZ600022A patent/NZ600022A/xx not_active IP Right Cessation
- 2008-08-08 UY UY31275A patent/UY31275A1/es not_active Application Discontinuation
- 2008-08-08 SG SG2013037619A patent/SG190657A1/en unknown
- 2008-08-08 CN CN2011102205939A patent/CN102276724A/zh active Pending
- 2008-08-08 TW TW103121994A patent/TW201512220A/zh unknown
- 2008-08-08 CL CL2008002349A patent/CL2008002349A1/es unknown
- 2008-08-08 CN CN200880102642A patent/CN101815725A/zh active Pending
- 2008-08-08 JP JP2010519473A patent/JP5325216B2/ja active Active
2009
- 2009-12-09 ZA ZA200908758A patent/ZA200908758B/xx unknown
- 2009-12-10 IL IL202645A patent/IL202645A/en active IP Right Grant
2010
- 2010-02-08 TN TNP2010000068A patent/TN2010000068A1/fr unknown
- 2010-02-09 EC EC2010009946A patent/ECSP109946A/es unknown
- 2010-02-09 MA MA32605A patent/MA32665B1/fr unknown
- 2010-02-09 CO CO10014090A patent/CO6251371A2/es not_active Application Discontinuation
- 2010-08-18 JP JP2010183075A patent/JP5238000B2/ja active Active
- 2010-09-17 US US12/884,563 patent/US20110165153A1/en not_active Abandoned
- 2010-12-02 HK HK16108880.8A patent/HK1220708A1/zh unknown
2011
- 2011-06-24 CL CL2011001592A patent/CL2011001592A1/es unknown
- 2011-08-03 EC EC2011009946A patent/ECSP11009946A/es unknown
2012
- 2012-08-22 CL CL2012002329A patent/CL2012002329A1/es unknown
2013
- 2013-07-19 JP JP2013150731A patent/JP2014039541A/ja not_active Withdrawn
- 2013-08-23 US US13/974,226 patent/US9078879B2/en active Active
- 2013-08-23 US US13/974,230 patent/US20140004110A1/en not_active Abandoned
2014
- 2014-08-11 PH PH12014501812A patent/PH12014501812A1/en unknown
2015
- 2015-04-22 US US14/693,047 patent/US9932399B2/en active Active
2016
- 2016-01-12 CY CY20161100025T patent/CY1117101T1/el unknown
2017
- 2017-03-16 AR ARP170100658A patent/AR107902A2/es unknown
2018
- 2018-02-15 US US15/897,400 patent/US20180186876A1/en not_active Abandoned
2020
- 2020-11-04 US US17/088,765 patent/US20210230271A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1220708A1 (zh)	2017-05-12
AU2008285590A1 (en)	2009-02-12
ECSP109946A (es)	2010-04-30
US20100189722A1 (en)	2010-07-29
HRP20160009T1 (hr)	2016-02-12
RS54359B1 (sr)	2016-04-28
PE20090499A1 (es)	2009-05-18
NZ600022A (en)	2013-11-29
CL2008002349A1 (es)	2009-10-23
ME02300B (me)	2016-06-20
US20110165153A1 (en)	2011-07-07
PE20140196A1 (es)	2014-03-19
JP5238000B2 (ja)	2013-07-17
CL2011001592A1 (es)	2012-02-17
DK2178915T3 (en)	2015-12-14
CN105273086A (zh)	2016-01-27
US9078879B2 (en)	2015-07-14
PT2178915E (pt)	2016-02-04
US9932399B2 (en)	2018-04-03
EP2178915B1 (en)	2015-10-14
AR071242A1 (es)	2010-06-09
AU2008285590B2 (en)	2014-08-14
PH12014501812B1 (en)	2016-10-24
PH12014501812A1 (en)	2016-10-24
US20140004110A1 (en)	2014-01-02
ZA200908758B (en)	2010-08-25
WO2009019312A2 (en)	2009-02-12
EA201000274A1 (ru)	2010-10-29
UY31275A1 (es)	2009-03-31
PE20120259A1 (es)	2012-04-04
CA2693464A1 (en)	2009-02-12
ES2555202T3 (es)	2015-12-29
ECSP11009946A (es)	2011-09-30
MY157555A (en)	2016-06-30
JP2010535483A (ja)	2010-11-25
JP5325216B2 (ja)	2013-10-23
WO2009019312A3 (en)	2009-04-30
UA105445C2 (en)	2014-05-12
CN101815725A (zh)	2010-08-25
KR101593403B1 (ko)	2016-02-12
TN2010000068A1 (en)	2011-09-26
CL2012002329A1 (es)	2012-12-21
EP2178915A2 (en)	2010-04-28
CY1117101T1 (el)	2017-04-05
CN103396490A (zh)	2013-11-20
IL202645A (en)	2016-03-31
CO6251371A2 (es)	2011-02-21
EP2562187A1 (en)	2013-02-27
JP2011004758A (ja)	2011-01-13
AR107902A2 (es)	2018-06-28
KR20100054791A (ko)	2010-05-25
NZ583713A (en)	2012-07-27
UA103005C2 (en)	2013-09-10
TW201512220A (zh)	2015-04-01
TWI535733B (zh)	2016-06-01
US20140010808A1 (en)	2014-01-09
EP2241577A1 (en)	2010-10-20
JP2014039541A (ja)	2014-03-06
US20180186876A1 (en)	2018-07-05
EA201200994A1 (ru)	2012-12-28
HUE026221T2 (en)	2016-05-30
EP2562187B1 (en)	2019-03-27
SI2178915T1 (sl)	2016-01-29
EA027499B1 (ru)	2017-08-31
CN102276724A (zh)	2011-12-14
BRPI0815369A2 (pt)	2013-03-12
BRPI0823331A2 (pt)	2013-07-30
IL202645A0 (en)	2011-08-01
US20160137729A1 (en)	2016-05-19
US20210230271A1 (en)	2021-07-29
TW200916478A (en)	2009-04-16
SG190657A1 (en)	2013-06-28
MA32665B1 (fr)	2011-10-02
CA2693464C (en)	2017-10-24

Publication	Publication Date	Title
IL202645A0 (en)	2011-08-01	Anti cd37 antibodies
GB0708002D0 (en)	2007-06-06	Antibodies
PT2374883T (pt)	2016-10-20	Anticorpo anti-cd4
PT2146745E (pt)	2015-10-14	Anticorpo pentaespecífico
EP2138576A4 (en)	2011-02-23	ANTI-CLAUDIN-4 ANTIBODY
SI2200700T1 (sl)	2016-04-29	Nova protitelesa
EP2331579A4 (en)	2013-01-23	MONOCLONAL ANTIBODIES
GB0821100D0 (en)	2008-12-24	Antibodies
IL206715A0 (en)	2010-12-30	Anti mif antibodies
IL200168A0 (en)	2010-04-15	Monoclonal anti-cxcl13 antibodies
GB0718737D0 (en)	2007-11-07	Antibodies
IL201983A (en)	2015-03-31	Antibody against pan nrpa
IL205073A0 (en)	2010-11-30	Anti-bst2 antibody
IL201552A0 (en)	2010-05-31	Antibodies against il-25
GB0702888D0 (en)	2007-03-28	Novel Antibodies
IL207581A0 (en)	2010-12-30	Anti-tyrp1 antibodies
ZA201007976B (en)	2012-02-29	Anti-pirb antibodies
GB0818356D0 (en)	2008-11-12	Antibodies
GB0724185D0 (en)	2008-01-23	Antibodies
HK1136590A (en)	2010-07-02	Anti-mdl-1 antibodies
HK1139961A (en)	2010-09-30	Non-fucosylated antibodies
AU2008903401A0 (en)	2008-07-24	Anti-C5L2 monoclonal antibodies
GB0806230D0 (en)	2008-05-14	Antibodies
GB0823562D0 (en)	2009-01-28	Antibodies
HK1146067A (en)	2011-05-13	Anti-tyrp1 antibodies